Associations of visceral adipose tissue adipokines with metabolic disorders in abdominal obesity

Aim. To identify associations of visceral adipose tissue adipokines with metabolic disorders in abdominal obesity.
Materials and methods. The study included 101 individuals aged 25–65 years (51 men). For all patients, questionnaires were completed, anthropometric measurements and 3 measurements of blood pressure were performed, fasting blood was sampled, and biopsies of visceral adipose tissue were collected during elective surgery. The parameters of the lipid profile and glucose levels were determined in the blood by enzymatic methods. Homogenates from biopsies of visceral adipose tissue were prepared. The blood levels of adiponectin, adipsin, lipocalin-2, plasminogen activator inhibitor type 1 (PAI-1), and resistin were measured, and homogenates of adipose tissue were obtained by the multiplex analysis. Sex hormone levels in the blood of all patients (estradiol in women, testosterone in men) were determined by the enzyme-linked immunosorbent assay (ELISA) kits.
Results. We identified correlations between serum levels of adipsin and adipose tissue and between adipsin from adipose tissue and PAI-1 in the blood serum. A weak negative relationship was found between the level of adiponectin and waist circumference, body mass index, and insulin resistance indices: triglyceride glucose index (TyG), lipid accumulation product (LAP), and visceral adiposity index (VAI). The level of adiponectin in visceral adipose tissue was inversely correlated with overweight in males and in the 45–65 age group. The level of resistin in visceral adipose tissue showed an inverse correlation with diastolic blood pressure, which persisted in the age group of 25–44 years.
Conclusion. Of the studied adipokines, a relationship with cardiometabolic parameters was shown for adiponectin and resistin. At the same time, adiponectin was inversely correlated with overweight in the group of men and in the age group of 45–65 years, while resistin was inversely correlated with diastolic blood pressure in the age group of 25–44 years.

1. Powell-Wiley T.M., Poirier P., Burke L.E., Després J.P., Gordon-Larsen P., Lavie C.J. et al. Obesity and сardiovascular вisease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–e1010. DOI: 10.1161/CIR.0000000000000973/

2. Lee J.J., Pedley A., Hoffmann U., Massaro J.M., Levy D., Long M.T. Visceral and Intrahepatic Fat Are Associated with Cardiometabolic Risk Factors Above Other Ectopic Fat Depots: The Framingham Heart Study. The American Journal of Medicine. 2018;131(6):684–692.e12. DOI: 10.1016/j.amjmed.2018.02.002/

3. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends in endocrinology and metabolism: TEM. 2000;11(8):327–332. DOI: 10.1016/s1043-2760(00)00301-5

4. Zhang Y., Yu M., Dong J., Wu Y., Tian W. Identification of novel adipokines through proteomic profiling of small extracellular vesicles derived from adipose tissue. J. Proteome Res. 2020;19(8):3130–3142. DOI: 10.1021/acs.jproteome.0c00131.

5. Груздева О.В., Дылева Ю.А., Белик Е.В., Акбашева О.Е., Бородкина Д.А., Синицкий М.Ю. и др. Экспрессия адипоцитокинов в жировых депо сердца в зависимости от степени атеросклероза коронарных артерий у пациентов с ишемической болезнью сердца. Вестник РАМН. 2021;76(2):159–168.

6. Полякова Е.А., Колодина Д.А., Мирошникова В.В., Разгильдина Н.Д., Богданова Е.О., Ляпина Е.Н. и др. Экспрессия гена лептина в эпикардиальной и подкожной жировой ткани у больных ишемической болезнью сердца. Трансляционная медицина. 2019;6(3):25–35. DOI: 10.18705/2311-4495-2019-6-3-25-35.

7. Белик Е.В., Груздева О.В., Дылева Ю.А., Бычкова Е.Е., Кузьмина А.А., Иванов С.В. и др. Особенности продукции ингибитора активатора плазминогена-1 локальными жировыми депо различной локализации при сердечно-сосудистых заболеваниях. Российский кардиологический журнал. 2022;27(4):4866. DOI: 10.15829/1560-4071-2022-4866.

8. Побожева И.А., Разгильдина Н.Д., Полякова Е.А., Пантелеева А.А., Беляева О.Д., Нифонтов С.Е. и др. Экспрессия гена адипонектина в эпикардиальной и подкожной жировой ткани при ишемической болезни сердца. Кардиология. 2020;60(4):62–69. DOI: 10.18087/cardio.2020.4.n517.

9. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1972;18(6):499–502.

10. Руяткина Л.А., Руяткин Д.С., Исхакова И.С. Возможности и варианты суррогатной оценки инсулинорезистентности. Ожирение и метаболизм. 2019;16(1):27–32. DOI: 10.14341/omet10082.

11. Taylor E.B. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin. Sci. (Lond.).

12. ;135(6):731–752. DOI: 10.1042/CS20200895.

13. Pittas A.G., Joseph N.A., Greenberg A.S. Adipocytokines and insulin resistance. The Journal of clinical endocrinology and metabolism. 2004;89(2):447–452. DOI:10.1210/jc.2003-031005

14. Sirbu A.E., Buburuzan L., Kevorkian S., Martin S., Barbu C., Copaescu C. et al. Adiponectin expression in visceral adiposity is an important determinant of insulin resistance in morbid obesity. Endokrynologia Polska. 2018;69(3):252–258. DOI: 10.5603/EP.a2018.0026.

15. Hörbelt T., Tacke C., Markova M., Herzfeld de Wiza D., Van de Velde F., Bekaert M. et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia. 2018;61(9):2054–2065. DOI: 10.1007/s00125-018-4636-9.

16. Jonas M.I., Kurylowicz A., Bartoszewicz Z., Lisik W., Jonas M., Domienik-Karlowicz J. et al. Adiponectin/resistin interplay in serum and in adipose tissue of obese and normal-weight individuals. Diabetology & Metabolic Syndrome. 2017;9:95. DOI: 10.1186/s13098-017-0293-2.

17. Acquarone E., Monacelli F., Borghi R., Nencioni A., Odetti P. Resistin: A reappraisal. Mechanisms of Ageing and Development. 2019;178:46–63. DOI: 10.1016/j.mad.2019.01.004.

18. Patel L., Buckels A.C., Kinghorn I.J., Murdock P.R., Holbrook J.D., Plumpton C. et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochemical and Biophysical Research Communications. 2003;300(2):472–476. DOI: 10.1016/s0006-291x(02)02841-3.

19. Wijetunge S., Ratnayake R.M.C.J., Kotakadeniya H.M.S.R.B., Rosairo S., Albracht-Schulte K., Ramalingam L. et al. Association between serum and adipose tissue resistin with dysglycemia in South Asian women. Nutrition & Diabetes. 2019;9(1):5. DOI: 10.1038/s41387-019-0071-3.

20. Papadopoulos D.P., Makris T.K., Krespi P.G., Poulakou M., Stavroulakis G., Hatzizacharias A.N. et al. Adiponectin and resistin plasma levels in healthy individuals with prehypertension. Journal of Clinical Hypertension (Greenwich, Conn.). 2005;7(12):729–733. DOI: 10.1111/j.1524-6175.2005.04888.x.

21. Zhang L., Curhan G.C., Forman J.P. Plasma resistin levels associate with risk for hypertension among nondiabetic women. Journal of the American Society of Nephrology: JASN. 2010;21(7):1185–1191. DOI: 10.1681/ASN.2009101053.

22. Zhang Y., Li Y., Yu L., Zhou L. Association between serum resistin concentration and hypertension: A systematic review and meta-analysis. Oncotarget. 2017;8(25):41529–41537. DOI: 10.18632/oncotarget.17561.

23. Jiang Y., Lu L., Hu Y., Li Q., An C., Yu X. et al. Resistin induces hypertension and insulin resistance in mice via a TLR4-dependent pathway. Scientific Reports. 2016;6:22193. DOI: 10.1038/srep22193.

24. Chen C., Jiang J., Lü J.M., Chai H., Wang X., Lin P.H. et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. American Journal of Physiology. Heart and Circulatory Physiology. 2010;299(1):H193–H201. DOI: 10.1152/ajpheart.00431.2009.